ARREPATH
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
ARREPATH
Industry:
Biotechnology Health Care Medical
Founded:
2022-01-01
Address:
Princeton, New Jersey, United States
Country:
United States
Website Url:
http://www.arrepath.com
Total Employee:
11+
Status:
Active
Total Funding:
20 M USD
Technology used in webpage:
Euro Cloudflare Hosting
Similar Organizations
Auris Health
Auris Health engages in the development of robotics technology for medical applications.
Avid Biosciences
Avid Bioservices' expansion will double existing capacity to service both a $40m backlog and its owner Peregrine.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Cutera
Cutera’s key messaging is directed to physicians specializing in cosmetic procedures.
DNA Script
DNA Script is a disruptive DNA synthesis company harnessing biology to accelerate breakthroughs in life science and human health.
Getinge
Getinge identifies customer issues and promotes clinical and economic benefits and follow and support the customer decision process.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
MorphoSys
MorphoSys is a biotechnology company focused on the research and development of fully human antibodies.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Board_member
Board_member
Board_member
Investors List
AriMed Advisors
AriMed Advisors investment in Seed Round - ArrePath
PTX Capital
PTX Capital investment in Seed Round - ArrePath
Innospark Ventures
Innospark Ventures investment in Seed Round - ArrePath
Viva BioInnovator
Viva BioInnovator investment in Seed Round - ArrePath
Insight Partners
Insight Partners investment in Seed Round - ArrePath
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - ArrePath
Nor'easter Ventures
Nor'easter Ventures investment in Seed Round - ArrePath
Official Site Inspections
http://www.arrepath.com
- Host name: 172.67.180.252
- IP address: 172.67.180.252
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ArrePath"
About - Arrepath
Kurt is a leader in the field of imaging and data sciences and , prior to joining ArrePath, was Senior Director Data Science at Zymergen, where he oversaw the building of a wide variety of …See details»
ArrePath - Crunchbase Company Profile & Funding
Organization. ArrePath . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... ArrePath is an …See details»
ArrePath - LinkedIn
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art ...See details»
ArrePath Company Profile: Overview and Full News Analysis
ArrePath, a company based in New Jersey, is dedicated to deciphering biology and discovering new anti-infectives through deep phenotypic insights and machine learning. With the rise of …See details»
Boehringer backs AI-powered anti-infective startup ArrePath
Mar 7, 2022 ArrePath hopes that its platform will generate brand new anti-infective classes that could overcome the increasing problem of antimicrobial resistance (AMR), which causes at …See details»
ArrePath Company Profile - Office Locations, Competitors ... - Craft
ArrePath is a company that develops anti-infective drugs using AI and machine learning technologies. It offers an ML-based imaging drug discovery platform that enables the …See details»
ArrePath - Funding, Financials, Valuation & Investors - Crunchbase
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
ArrePath Announces $20 Million Seed Financing to …
Mar 3, 2022 A report by the World Health Organization previously estimated that 750,000 people die each year from resistant infections worldwide but this number has recently been updated. ... ArrePath is an ...See details»
ArrePath Announces $20 Million Seed Financing
Mar 7, 2022 A report by the World Health Organization previously estimated that 750,000 people die each year from resistant infections worldwide but this number has recently been updated. ... ArrePath is an ...See details»
ArrePath Announces $20 Million Seed Financing to Advance its …
Mar 3, 2022 A report by the World Health Organization previously estimated that 750,000 people die each year from resistant infections worldwide but this number has recently been updated. …See details»
Press Releases Archives - Arrepath
Nov 19, 2024 About ArrePath. ArrePath was founded with the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the …See details»
Arrepath - Viva BioInnovator
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art …See details»
ArrePath Announces $20 Million Seed Financing to Advance its …
A report by the World Health Organization previously estimated that 750,000 people die each year from resistant infections worldwide but this number has recently been updated. ... About …See details»
Platform - Arrepath
Our Platform’s Proof-of-Concept. Proof-of-concept of the ArrePath platform has been demonstrated in studies published in Cell by our scientific founder, Professor Zemer Gitai, Ph. …See details»
ArrePath Secures £1 Million Grant from PACE to Advance Novel ...
Nov 19, 2024 About ArrePath ArrePath was founded with the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the …See details»
Arrepath — Nor'easter Ventures
Mar 3, 2022 ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections, ... A report by the World Health Organization previously …See details»
ArrePath Announces $20 Million Seed Financing to Advance its
Mar 3, 2022 ArrePath, announced today that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new …See details»
News & Media - Arrepath
ArrePath will be presenting at the BioNJ BioPartnering event on May 14th at Liberty Science Center in Jersey City, NJ! Join us in the Delta Lab at 10:50 AM – 12:10 PM. The BioNJ …See details»
Strategy - Arrepath
ArrePath Technology and Pipeline. We are evolving our machine learning and artificial intelligence technologies and building a pipeline of anti-infective programs representing under- and …See details»